CIK 0000879169 · Large accelerated filer
INCYTE CORP
Sign in to watch- Ticker
- INCY
- Exchange
- Nasdaq
- Industry
- Services-Commercial Physical & Biological Research
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 943136539
- Phone
- 3024986700
- Business address
- 1801 AUGUSTINE CUT-OFF, WILMINGTON, DE, 19803
- Former names
- INCYTE INC, INCYTE GENOMICS INC, INCYTE PHARMACEUTICALS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $32,959,897
- in 5 filings, $33.0M under 10b5-1 plans
Net −$32,959,897. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-06-08 | HARRIGAN EDMUND Director | Grant or award · Non Qualfied Stock Option (right to buy) | +6,111 | 6,111 | ||
| 2026-06-04 | Tray Thomas Principal Accounting Officer | Option exercise 10b5-1 | +2,639 | $83.83 | $221K | 23,771 |
| 2026-06-04 | Tray Thomas Principal Accounting Officer | Sale 10b5-1 | −2,639 | $100.00 | $264K | 21,132 |
| 2026-06-04 | Tray Thomas Principal Accounting Officer | Option exercise · Non-Qualified Stock Option (right to buy) 10b5-1 | −2,639 | 0 | ||
| 2026-06-01 | CAGNONI PABLO J President, Global Head of R&D | Shares withheld for taxes | −25,469 | $95.59 | $2.4M | 240,848 |
| 2026-05-26 | Tray Thomas Principal Accounting Officer | Sale 10b5-1 | −2,051 | $97.35 | $200K | 21,132 |
| 2026-05-26 | BIENAIME JEAN JACQUES Director | Option exercise 10b5-1 | +15,000 | $84.53 | $1.3M | 35,841 |
| 2026-05-26 | BIENAIME JEAN JACQUES Director | Shares withheld for taxes 10b5-1 | −13,059 | $97.10 | $1.3M | 22,782 |
| 2026-05-26 | BIENAIME JEAN JACQUES Director | Option exercise · Non-Qualified Stock Option (right to buy) 10b5-1 | −15,000 | 0 | ||
| 2026-05-19 | Clancy Paul J Director | Option exercise 10b5-1 | +15,000 | $84.53 | $1.3M | 38,741 |
| 2026-05-19 | Clancy Paul J Director | Sale 10b5-1 | −15,000 | $94.93 | $1.4M | 23,741 |
| 2026-05-19 | Clancy Paul J Director | Option exercise · Non-Qualified Stock Option (right to buy) 10b5-1 | −15,000 | 0 | ||
| 2026-05-08 | BAKER BROS. ADVISORS LP Director | Option exercise | +15,000 | $84.53 | $1.3M | 2,833,039 |
| 2026-05-08 | BAKER BROS. ADVISORS LP Director | Option exercise | +15,000 | $84.53 | $1.3M | 28,203,718 |
| 2026-05-08 | BAKER BROS. ADVISORS LP Director | Option exercise · Non-Qualified Stock Options | −15,000 | 0 | ||
| 2026-05-08 | BAKER BROS. ADVISORS LP Director | Option exercise · Non-Qualified Stock Options | −15,000 | 0 | ||
| 2026-05-06 | Stein Steven H CMO & Head of Late-Stage Dev. | Grant or award | +44,124 | 78,327 | ||
| 2026-05-06 | CAGNONI PABLO J President, Global Head of R&D | Grant or award | +31,517 | 266,317 | ||
| 2026-05-04 | Upadhyay Suketu EVP & Chief Financial Officer | Grant or award | +26,343 | 26,343 | ||
| 2026-05-04 | Upadhyay Suketu EVP & Chief Financial Officer | Grant or award · Employee Stock Option (right to buy) | +38,429 | 38,429 |
Page 10 of 15 · 293 trades